Literature DB >> 18579075

Glioma stem cells: a midterm exam.

Charles D Stiles1, David H Rowitch.   

Abstract

Several years ago, the discovery of a highly tumorigenic subpopulation of stem-like cells embedded within fresh surgical isolates of malignant gliomas lent support to a new paradigm in cancer biology--the cancer stem cell hypothesis. At the same time, these "glioma stem cells" seemed to resolve a long-standing conundrum on the cell of origin for primary cancers of the brain. However, central tenets of the cancer stem cell hypothesis have recently been challenged, and the cellular origins of stem-like cells within malignant glioma are still contended. Here, we summarize the issues that are still in play with respect to the cancer stem cell hypothesis, and we revisit the developmental origins of malignant glioma. Do glioma stem cells arise from developmentally stalled neural progenitors or from dedifferentiated astrocytes? Five separate predictions of a neural progenitor cell of origin are put to the test.

Entities:  

Mesh:

Year:  2008        PMID: 18579075     DOI: 10.1016/j.neuron.2008.05.031

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  145 in total

Review 1.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

2.  Activation of postnatal neural stem cells requires nuclear receptor TLX.

Authors:  Wenze Niu; Yuhua Zou; Chengcheng Shen; Chun-Li Zhang
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

Review 3.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

4.  Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells.

Authors:  Mingyao Ying; Yingying Sang; Yunqing Li; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa; Angelo L Vescovi; Charles G Eberhart; Shuli Xia; John Laterra
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

5.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

Review 6.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

7.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

8.  Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.

Authors:  Nusrat Jahan; Jae M Lee; Khalid Shah; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-07-19       Impact factor: 7.396

9.  Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15.

Authors:  Xing-Gang Mao; Xiang Zhang; Xiao-Yan Xue; Geng Guo; Peng Wang; Wei Zhang; Zhou Fei; Hai-Ning Zhen; Si-Wei You; Hao Yang
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis.

Authors:  Francesco Niola; Xudong Zhao; Devendra Singh; Ryan Sullivan; Angelica Castano; Antonio Verrico; Pietro Zoppoli; Dinorah Friedmann-Morvinski; Erik Sulman; Lindy Barrett; Yuan Zhuang; Inder Verma; Robert Benezra; Ken Aldape; Antonio Iavarone; Anna Lasorella
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.